Preview Mode Links will not work in preview mode

May 6, 2022

Featuring perspectives from Dr Ross Camidge, including the following topics:

  • Introduction: First-line systemic treatment; brain metastases (0:00)
  • Case: A woman in her early 60s with squamous NSCLC metastatic to tbe brain and an ALK rearrangement; PD-L1 TPS 70% — Spencer Henick Bachow, MD (20:30)
  • Case: A man in his early 70s with localized NSCLC with an ALK rearrangement and significant comorbidities — Sunil Gandhi, MD (24:44)
  • Case: A woman and heart transplant recipient in her mid 70s with metastatic NSCLC with a KRAS G12C mutation; PD-L1 TPS 20% — Mamta Choksi, MD (30:26)
  • Case: A woman in her late 70s with metastatic NSCLC and a MET exon 14 skipping mutation — Jennifer L Dallas, MD (36:01)
  • Case: A woman in her late 60s with metastatic NSCLC and a HER2 exon 19 mutation pathogenic variant; PD-L1 TPS 15% — Rajni Sinha, MD, MRCP (41:43)
  • Case: A man in his early 30s with metastatic NSCLC and an NTRK fusion; PD-L1 TPS 10% — Daniel R Carrizosa, MD, MS (46:09)
  • Treatment for Patients with ROS1 Fusions (48:34)
  • RET Fusions in Lung Cancer (52:38)
  • BRAF Mutations (54:20)
  • NRG Fusions (55:31)

CME information and select publications